 |
Kambiz Kalantarinia, M.D. Associate Professor of Medicine Department of Medicine, Division of Nephrology
M.D., 1990: Shiraz University, Iran |
|
Phone 434-924-5125 | Fax 434-924-5848 | Email kk6c@virginia.edu |
|
My main research interests include: (1) ultrasound imaging of the kidney and the use of novel techniques of contrast enhanced ultrasound (CEU) in monitoring the changes in total and regional renal blood flow; (2) hemodialysis vascular access, specifically factors leading to failure to mature among the arteriovenous fistulae (AVF), and study of potential predictors of AVF maturation; and (3) pathways involved in the development and progression of diabetic kidney disease, especially the role of inflammatory molecules Currently, I have an NIH Career Development Award (K23) to study the potential therapeutic effect of an experimental antiinflammatory agent in patients with type 2 diabetes and kidney disease. In this study I will be utilizing CEU to monitor the potential renal hemodynamic changes. I am also running a few pilot studies at the UVa General Clinical Research Center (GRCR). These include a study of CEU in normal volunteers to monitor changes in renal blood flow in response to physiologic stimuli, and a study of correlation between degree of albuminuria and urinary concentration of inflammatory cytokines, chemokines, and growth factors in type 2 diabetic individuals. My clinical interests include: (1) Hemodialysis vascular access. As director of the UVa Hemodialysis Vascular Access Program, I am constantly involved in development of new protocols and strategies to improve the rate of AVF and outcomes. We have established a multidisciplinary team to address this issue. In collaboration with the UVa ITC department, I am developing a comprehensive, web-based hemodialysis access database. This would provide a wonderful opportunity for future research and quality improvement projects; (2) Diabetic kidney disease, new treatments and diagnostic approaches; (3) Kidney ultrasonography and real-time ultrasound guidance for native and transplant kidney biopsies; (4) Bone disease in chronic kidney disease and secondary hyperparathyroidism. This is a relatively complicated field with many controversies among authorities on the goals of treatment and strategies used to achieve those goals; and (5) Care of patients with ESRD on hemodialysis. PubMed Search for articles by faculty member » References Liu J, Kalantarinia K, Rosner MH. Management of lipid abnormalities associated with end-stage renal disease. Sem Dialysis. 2006;19(5):391-401. Kalantarinia K, Okusa MD. The renin-angiotensin system and its blockade in diabetic renal and cardiovascular disease. Curr Diabetes Rep. 2006;6(1):8-16. Kalantarinia K, Awad AS, Siragy HM. Urinary and renal interstitial concentrations of TNF-alpha increase prior to the rise in albuminuria in diabetic rats. Kidney Int. 2003;64(4):1208-1213. Kalantarinia K, Siragy HM. The choice of antihypertensive drugs in patients with diabetes: angiotensin II and beyond. Curr Diabetes Rep. 2002;2(5):423-430. |